



## COVID-END partners coordination call

Notes from 11 June 2020

<https://zoom.us/j/6163788736>

### 1. INTRODUCTIONS

- a. *Jeremy welcomed new participants in the partner calls (see attachment 2)*
  - i. *Stephanie Chang, Evidence-based Practice Centers, Agency for Healthcare Research and Quality, U.S.*
  - ii. *Rhona Mijumbi (who had joined one previous call) and Edward Kayongo, ACRES (Centre for Rapid Evidence Synthesis), Makerere University, Uganda*
  - iii. *Kaelan Moat, McMaster Health Forum, Canada*

### 2. FOLLOW UP ON ACTION ITEMS

- a. *Jeremy pointed partners to three background documents*
  - i. *Partner notes from 4 June (see attachment 3)*
  - ii. *Co-chairs meeting notes from 8 June (see attachment 4)*
  - iii. *Action items (see attachment 5)*

### 3. COVID-END NETWORK UPDATES

- a. *Jeremy proposed a new structure for these partner meetings to allow for more in-depth discussion by 1-2 working groups per meeting*
  - i. *Review progress and discuss strategic future directions (in 15-20 min)*
  - ii. *Once a month, provide high-level overview across working groups*
- b. *Jeremy walked the group through a slide presentation about potential 'next generation' ideas for COVID-END (see attachment 6), and particularly invited feedback on several points*
  - i. *Three proposed principles to guide activities*
    - i. *No specific feedback provided on the principles*
  - ii. *Four proposals that would be the focus for significant Secretariat and working group activity*
    - 1. *Inventory of evidence products that targets decision-makers, can be filtered using the COVID-END taxonomy, and can be scanned easily for decision-relevant information (e.g., quality rating, date stamping, countries where included studies were conducted)*
      - a. *Feedback included: 1) could the inventory support further rationalization / collaboration across the primary study inventories? - addendum: other databases – see agenda items 4 and 6 below – may be better positioned to address this; 2) should we collate the various stakeholders we consider 'decision makers,' create a list of their evidence needs/questions, and then either guide them to evidence via COVID-END (pull) and/or provide a service (push) the best available evidence based on our judgements? - addendum: the Secretariat has been acting on the assumption that the decision-makers are primarily practitioners and policymakers in the four*

*domains covered by the COVID-END taxonomy, that the taxonomy provides the list, and that the inventory could support pull and push mechanisms, but welcomes feedback if partners have different views; 3) does the inventory introduce a significant risk of pathway disruption for end users, especially in relation to groups who have established dissemination pathways - addendum: the inventory is an enabler for any partner that wishes to use it as part of their established dissemination pathways (and certainly shouldn't interfere with established dissemination pathways)*

2. **COVID-END Community that will be engaged through a listserv with opportunities for bi-weekly discussion topics, sharing experiences, etc.**
  - a. **No specific feedback provided on this point**
3. **Horizon scanning with a focus on engaging a small group of thoughtful decision-makers who can help us to identify future evidence needs related to public-health measures, clinical management of COVID-19 and pandemic-related health issues, health-system arrangements, and economic and social responses**
  - a. **Feedback included: 1) do we need a global group, multiple regional and linguistic groups (given decision-makers typically invited to global panels often aren't in close contact with the challenges faced by frontline practitioners and local policymakers**
4. **Core set of living systematic reviews on the 'big issues' where decisions will continue to be made as the pandemic and pandemic response enter different phases**
  - a. **No specific feedback provided on this point**
5. **ACTION: Partners to continue to provide feedback as they reflect further on these opportunities and Secretariat to continue to reflect on this feedback and find appropriate ways to act on it**

#### 4. PRESENTATION FROM DIGITIZING GROUP

- a. *Kaelan presented an update from the Digitizing working group (see the second version of attachment 7, which was circulated just before the call to replace a version that was originally sent out)*
  - i. *Principles that are guiding the collaboration among participants to the working group*
  - ii. *Desire for a single source, and the group has identified facilitators, barriers, and bridging work that is already underway (e.g., 'improve my RISE file' service)*
  - iii. *Desire for highlighting decision-relevant information, and again the working has identified facilitators and barriers*
  - iv. *Desire for including all types of decision-relevant documents, and again the working group has identified facilitators and barriers*
  - v. *Criteria for solutions include that they are technically feasible, economically viable, and based on sound assumptions*
- b. *Feedback included: 1) it's important to distinguish the inventory described above (i.e., an inventory of evidence products that targets decision-makers, can be filtered using a robust taxonomy, and can be scanned easily for decision-relevant information (e.g., quality rating, date stamping, countries where included studies were conducted)) from other uses cases for one-stop shops (e.g., a single source that emphasizes comprehensiveness across all reviews and studies regardless of decision relevance, etc.,*

*which is the direction that some other partners are appropriately pursuing and COVID-END should not compete with them in this work); 2) working group members may want to consider a call for proposals (<https://medium.com/covidaction/open-call-building-resilient-health-systems-through-the-covid-19-pandemic-and-beyond-1d3b73861f15>); 3) McMaster PLUS has made available a demo of the 'Improve my RIS file' service (<https://plus.mcmaster.ca/COVID-19/RIS>); and 4) Cochrane has a working model as part of their Cochrane C-19 register (where you can insert a list of PubMed IDs or NCT IDs into the regular search box and receive a set of results that can be exported as RIS or CSV with the information and metadata enrichment that Cochrane folks have added)*

- c. ACTION: Partners to consider trying one or both of these demos and to send any feedback to the Digitizing working group

## 5. UPDATES FROM OTHER WORKING GROUPS

- a. *David provided a brief update on the newly developed document for those considering and conducting evidence syntheses (see attachment 8), which will be made available both as a document on the COVID-END website and in an easily navigable way on multiple COVID-END webpages*
- b. *Linn noted that the visual David showed could also be linked to the tasks for the digitizing group (to show where their proposed or ongoing solutions fit)*

## 6. UPDATES ON CROSS-PARTNER INITIATIVES AND INITIATIVES OF INTEREST TO PARTNERS

- a. *Gabriel Rada described Epistemonikos' COVID-19 L\*VE collection: <https://app.iloveevidence.com/covid19> (see attachment 9) which also includes a pilot of the Enhance my RIS feature*
- b. *Nikita Burke described two upcoming Evidence Synthesis Ireland webinars (the recordings for which are recorded and both the registration and recordings can be found here: <https://evidencesynthesisireland.ie/training/>*
- i. *Drs Catherine Houghton and Linda Biesty (Evidence Synthesis Ireland) "Rapid Qualitative Evidence Synthesis: Balancing rigour with speed" Qualitative Evidence Synthesis (QES) during, and in response to, the COVID-19 pandemic. June 18<sup>th</sup> 12 pm (BST)*
- ii. *Dr Andrea Tricco on conducting rapid reviews and how to tailor rapid review methods according to decision-makers information needs. July 23<sup>rd</sup> 2pm (BST)*

## 7. ANY OTHER BUSINESS

- a. *No other business*